Chiropractors in Eureka, MT Accepting Medicare
5 Chiropractors found. Showing 1 - 5
 Dr. Jack D West, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 198 14 St E, Eureka, MT 59917 Phone: 406-297-2811 |
 Dr. Alice Bain Elrod, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 403 Dewey Ave., Elrod Chiropractic, Eureka, MT 59917 Phone: 406-297-3422 |
Jenny M Komac, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 110 Dewey Ave, Eureka, MT 59917 Phone: 406-297-2999 Fax: 406-297-7999 |
Dr. Jenna Beth Steiner, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 110 Dewey Ave, Eureka, MT 59917 Phone: 406-297-2999 |
 Eureka Family Chiropractic P.c. Chiropractor Medicare: Medicare Enrolled Practice Location: 110 Dewey Ave, Eureka, MT 59917 Phone: 406-297-2999 Fax: 406-297-7999 |
News Archive
Simple pull-to-sit task could predict risk of ASD in infants
A new prospective study of six-month-old infants at high genetic risk for autism identified weak head and neck control as a red flag for autism spectrum disorder (ASD) and language and/or social developmental delays.
Emanuel reassures Democrats on public insurance option
"White House Chief of Staff Rahm Emanuel reassured House Democrats on Tuesday night that President Barack Obama strongly backs a government-run health insurance plan, seeking to quell a firestorm among liberals upset at Emanuel's comments in the Wall Street Journal that suggested such a plan could be delayed," Roll Call reports.
CHS prices $1.0 billion senior notes offering
Community Health Systems, Inc., announced today that on March 7, 2012, its wholly-owned subsidiary, CHS/Community Health Systems, Inc., priced an offering of $1.0 billion aggregate principal amount 8.00% senior notes due 2019 at an issue price of approximately 102.5%.
Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma
BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.
FDA updates Zelnorm labeling a treatment of women with irritable bowel syndrome
The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.
› Verified 6 days ago
Physical Therapists
Chiropractors
Occupational Therapists
Speech-Language Pathologists
Optometrists